Clinical Trials Logo

Neurofibromatosis 1 clinical trials

View clinical trials related to Neurofibromatosis 1.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT03259633 Approved for marketing - Clinical trials for NF type1 With Inoperable Plexiform Neurofibromas

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

Start date: n/a
Phase:
Study type: Expanded Access

This will be an open-label, single-arm, multicenter intermediate access protocol which provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1 (NF1) who have inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any alternative therapeutic options. All patients will continue to receive drug while they are deriving clinical benefit. Approximately 100 patients in the US will be treated as part of this protocol